Working… Menu

Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age (Prefer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01110356
Recruitment Status : Completed
First Posted : April 26, 2010
Last Update Posted : November 15, 2012
Information provided by (Responsible Party):
Vifor Inc.

Brief Summary:
research study of Ferric carboxymaltose to treat fatigue/exhaustion symptoms, believed to be due to iron deficiency.

Condition or disease Intervention/treatment Phase
Iron Deficiency Drug: Ferinject Other: Saline Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 294 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age
Study Start Date : June 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue Iron

Arm Intervention/treatment
Experimental: Ferinject Drug: Ferinject
Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.

Placebo Comparator: Saline Other: Saline
Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.

Primary Outcome Measures :
  1. To assess the efficacy of a single intravenous (IV) administration of FCM (1,000 mg) compared with placebo in improving fatigue symptoms in IDNA women of child bearing age. [ Time Frame: Day 56 ]

Secondary Outcome Measures :
  1. To compare efficacy of a single IV application of FCM with that of placebo on change of iron status on Day 56 (i.e., proportion of subjects with haemoglobin (Hb) ≥12 g/dL; serum-ferritin (s-ferritin) ≥50 ng/mL; transferrin saturation (TfS) >20%). [ Time Frame: Day 56 ]
  2. To determine the relationship between change in iron status (s-ferritin and TfS) and improvement of fatigue symptoms. [ Time Frame: Day 56 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent prior to study specific procedures.
  • Premenopausal, regularly menstruating women.
  • Age ≥18 years.
  • Body weight between 50 and 90 kg.
  • Haemoglobin ≥115 g/L.
  • Iron deficiency at screening defined as follows:

    • S-ferritin level <50 ng/mL, AND, TfS <20%, OR,
    • S-ferritin level <15 ng/mL.
  • Serum C-reactive protein:

    • <5 mg/L if not on oral contraception, OR,
    • <20 mg/L if use of oral contraception.
  • Minimum total score of 5 on the Piper Fatigue Scale (PFS) (mean of items 2 to 23).
  • Negative pregnancy test (serum human chorionic gonadotropin (hCG) at screening.
  • Normal levels of vitamin B12 and folic acid at screening.
  • Adequate contraception during the study period and for 1 month following study completion.
  • Availability and willingness to complete all study visits and procedures per protocol.

Exclusion Criteria:

  • Haemoglobin level <115 g/L.
  • Haemoglobinopathy.
  • Haemochromatose.
  • Major depressive disorder based on Patient Health Questionnaire (PHQ-9) (5 items with scores ≥2; one of which corresponds to question number 1 or 2).
  • Any active or unstable concurrent medical condition (e.g., cancer, renal dysfunction, liver dysfunction (aspartate aminotransferase (AST); alanine aminotransferase (ALT) >3-fold upper limit), angina (Class IV).
  • Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B virus or hepatitis C virus infection.
  • Chronic inflammatory disease (e.g., rheumatoid arthritis; inflammatory bowel disease).
  • Documented history of clinically significant level of sleep apnoea defined as 5 or more episodes per hour of any type of apnoea.
  • Intake of concurrent medications that could interfere with physical or mental performance (e.g., antidepressive, antihistamines, narcotic or any chemotherapeutic agents known to cause drowsiness).
  • Important recent weight loss (>10% within the past month).
  • Body weight <50 kg or >90 kg.
  • Thyroid dysfunction, thyroid stimulating hormone >4 μU/mL.
  • Intake of iron preparations 4 weeks prior to screening.
  • Use of gestagens e.g., Implanon, Mirena, Depo-Provera for menstruation repression (see Section 7.7, Prohibited Therapy or Concomitant Treatment, page 35).
  • Known hypersensitivity to FCM or to any other iron preparation.
  • Pregnancy (positive hCG test at screening) or breast feeding.
  • Participation in any other interventional trial within 4 weeks prior to screening.
  • Inability to fully comprehend and/or perform study procedures or provide written consent in the Investigator's opinion.
  • Subject is not using adequate contraceptive precautions during the study and for up to 1 month after the last dose of the study medication. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner.
  • Subject previously has entered this study.
  • Subject will not be available for follow-up assessments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01110356

Layout table for location information
Universitätsklinik für Frauenheilkunde
Vienna, Austria, 1090
Sponsors and Collaborators
Vifor Inc.
Layout table for investigator information
Principal Investigator: Bernard Favrat Quartier UNIL-CHUV

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Vifor Inc. Identifier: NCT01110356     History of Changes
Other Study ID Numbers: IDNA 2009-01
First Posted: April 26, 2010    Key Record Dates
Last Update Posted: November 15, 2012
Last Verified: November 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms
Ferric Compounds